Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Combined Detection of Serum MiR-221-3p and MiR-122-5p Expression in Diagnosis and Prognosis of Gastric Cancer

  • Zhang, Yan (Department of Gastroenterology, Taizhou First People's Hospital) ;
  • Huang, Huifeng (Department of Gastroenterology, Taizhou First People's Hospital) ;
  • Zhang, Yun (Department of Gastroenterology, Taizhou First People's Hospital) ;
  • Liao, Nansheng (Department of General Surgery, Taizhou First People's Hospital)
  • Received : 2019.05.26
  • Accepted : 2019.08.15
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the clinical value of serum miR-221-3p and miR-122-5p expression levels in the diagnosis and prognosis of gastric cancer. Materials and Methods: Serum samples from 141 gastric cancer cases (gastric cancer group), 110 gastric polyps (gastric polyp group), and 75 healthy people (healthy control) were used to detect miR-221-3p and miR-122-5p expression using real-time reverse transcription polymerase chain reaction. Results: Serum miR-221-3p expression was significantly higher in the gastric cancer group than in the gastric polyp group, and it was significantly lower than that before operation. The miR-221-3p expression was significantly higher in the death group than in the survival group. The proliferation and migration ability significantly increased and the apoptosis rate significantly decreased by miR-221-3p transfection in gastric cancer cells. In contrast, the function of miR-122-5p in gastric cancer cells was opposite of miR-221-3p. Serum miR-221-3p expression was negatively correlated with that of miR-122-5p in gastric cancer. Serum miR-221-3p and miR-122-5p expressions were significantly correlated with the degree of differentiation, tumor, node, metastasis stage, lymph node metastasis, and invasion depth. miR-221-3p and miR-122-5p expression levels were independent prognostic factors for postoperative gastric cancer. In the diagnosis and predicting prognosis of gastric cancer, receiver operating characteristic analysis revealed that the area under curve of combined detection of serum miR-221-3p and miR-122-5p expression had a greater diagnostic effect than either single maker. Conclusions: The miR-221-3p and miR-122-5p are involved in the development of gastric cancer, and they have important clinical values in gastric cancer diagnosis and prognosis.

Keywords

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. https://doi.org/10.3322/caac.21262
  2. Gatta G, Rossi S, Capocaccia R. Cancer burden estimates and forecasts: uses and cautions. Tumori 2013;99:439-443. https://doi.org/10.1177/030089161309900320
  3. Fu DG. Epigenetic alterations in gastric cancer (review). Mol Med Rep 2015;12:3223-3230. https://doi.org/10.3892/mmr.2015.3816
  4. Khatami F, Karbakhsh M. Socioeconomic position and incidence of gastric cancer: a systematic review and meta-analysis. J Epidemiol Community Health 2015;69:818-819. https://doi.org/10.1136/jech-2013-203784
  5. Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver 2015;9:5-17. https://doi.org/10.5009/gnl14118
  6. Stojanovic J, Tognetto A, Tiziano DF, Leoncini E, Posteraro B, Pastorino R, et al. MicroRNAs expression profiles as diagnostic biomarkers of gastric cancer: a systematic literature review. Biomarkers 2019;24:110-119. https://doi.org/10.1080/1354750X.2018.1539765
  7. Yuan HL, Wang T, Zhang KH. MicroRNAs as potential biomarkers for diagnosis, therapy and prognosis of gastric cancer. Onco Targets Ther 2018;11:3891-3900. https://doi.org/10.2147/OTT.S156921
  8. Wu Q, Ren X, Zhang Y, Fu X, Li Y, Peng Y, et al. MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. Biochem Biophys Res Commun 2018;497:1162-1170. https://doi.org/10.1016/j.bbrc.2017.01.002
  9. Deng L, Lei Q, Wang Y, Wang Z, Xie G, Zhong X, et al. Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis. Oncotarget 2017;8:108712-108725. https://doi.org/10.18632/oncotarget.21561
  10. Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR- 491-5p expression in colon cancer. Am J Transl Res 2014;6:391-401.
  11. Xu X, Gao F, Wang J, Tao L, Ye J, Ding L, et al. MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4. Cancer Biol Ther 2018;19:427-435. https://doi.org/10.1080/15384047.2018.1423925
  12. Barajas JM, Reyes R, Guerrero MJ, Jacob ST, Motiwala T, Ghoshal K. The role of miR-122 in the dysregulation of glucose-6-phosphate dehydrogenase (G6PD) expression in hepatocellular cancer. Sci Rep 2018;8:9105. https://doi.org/10.1038/s41598-018-27358-5
  13. Duan Y, Dong Y, Dang R, Hu Z, Yang Y, Hu Y, et al. MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells. Cell Biol Int 2018;42:1564-1574. https://doi.org/10.1002/cbin.11052
  14. Ergun S, Ulasli M, Igci YZ, Igci M, Kirkbes S, Borazan E, et al. The association of the expression of miR- 122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 2015;42:497-505. https://doi.org/10.1007/s11033-014-3793-2
  15. Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, et al. Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma. Clin Epigenetics 2018;10:11. https://doi.org/10.1186/s13148-018-0444-9
  16. Uen Y, Wang JW, Wang C, Jhang Y, Chung JY, Tseng T, et al. Mining of potential microRNAs with clinical correlation - regulation of syndecan-1 expression by miR-122-5p altered mobility of breast cancer cells and possible correlation with liver injury. Oncotarget 2018;9:28165-28175. https://doi.org/10.18632/oncotarget.25589
  17. Pei ZJ, Zhang ZG, Hu AX, Yang F, Gai Y. miR-122-5p inhibits tumor cell proliferation and induces apoptosis by targeting MYC in gastric cancer cells. Pharmazie 2017;72:344-347.
  18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008;105:10513-10518. https://doi.org/10.1073/pnas.0804549105
  19. Clancy C, Joyce MR, Kerin MJ. The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. Cancer Biomark 2015;15:103-113. https://doi.org/10.3233/CBM-140456
  20. Li M, Zhou Y, Xia T, Zhou X, Huang Z, Zhang H, et al. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat 2018;170:257-270. https://doi.org/10.1007/s10549-018-4757-3
  21. Wang X, Jia Z, Shi H, Pan C. Identification and evaluation of 2 circulating microRNAs for non-small cell lung cancer diagnosis. Clin Exp Pharmacol Physiol 2018;45:1083-1086. https://doi.org/10.1111/1440-1681.12977
  22. Ho AS, Huang X, Cao H, Christman-Skieller C, Bennewith K, Le QT, et al. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl Oncol 2010;3:109-113. https://doi.org/10.1593/tlo.09256
  23. Jones LB, Bell CR, Bibb KE, Gu L, Coats MT, Matthews QL. Pathogens and their effect on exosome biogenesis and composition. Biomedicines 2018;6:E79. https://doi.org/10.3390/biomedicines6030079
  24. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-17452. https://doi.org/10.1074/jbc.M110.107821
  25. Wu XG, Zhou CF, Zhang YM, Yan RM, Wei WF, Chen XJ, et al. Cancer-derived exosomal miR-221- 3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis 2019;22:397-410. https://doi.org/10.1007/s10456-019-09665-1
  26. Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene 2019;38:1256-1268. https://doi.org/10.1038/s41388-018-0511-x
  27. Liu YH, Liu JL, Wang Z, Zhu XH, Chen XB, Wang MQ. MiR-122-5p suppresses cell proliferation, migration and invasion by targeting SATB1 in nasopharyngeal carcinoma. Eur Rev Med Pharmacol Sci 2019;23:622-629.
  28. Xu Z, Liu G, Zhang M, Zhang Z, Jia Y, Peng L, et al. miR-122-5p inhibits the proliferation, invasion and growth of bile duct carcinoma cells by targeting ALDOA. Cell Physiol Biochem 2018;48:2596-2606. https://doi.org/10.1159/000492702

Cited by

  1. miR-3196 acts as a Tumor Suppressor and Predicts Survival Outcomes in Patients With Gastric Cancer vol.19, 2019, https://doi.org/10.1177/1533033820923427
  2. MicroRNAs as regulators of VEGFA and NFE2L2 in cancer vol.759, 2019, https://doi.org/10.1016/j.gene.2020.144994